US biotech dependence on China sparks security fears
Patents expiring for top drugs push Western pharma to partner with Chinese biotech firms, with Pfizer paying up to $650 million for Innovent and Bristol Myers Squibb tying up with Hengrui for up to $950 million, signaling a surge of US investment in Chinese biotech. Lawmakers are weighing tighter national-security rules as the USITC probes potential Chinese state backing, while investors remain divided on the implications for US drug development and global supply chains.